G-Tech Medical Appoints Rob Kirby as Vice President of Strategy and Business Development

Mountain View, Calif., November 5, 2021 – G-Tech Medical, a developer of non-invasive diagnostic solutions for patients with gastrointestinal disorders, today announced that Rob Kirby has been hired as Vice President of Strategy and Business Development.

“We are very excited that Rob has joined our company,” said Steve Axelrod, CEO of G-Tech. “As a startup we know that every hire is critical, and that adding versatile performers is especially important. Rob has demonstrated a rare ability in his career to succeed in many different roles. It’s also already clear that he will have a strong cultural fit with our small but growing team.”

Rob has worked for over 20 years in medical device startup companies. His breadth of experience includes strategic planning, business development, marketing and cross-functional program leadership. He has held leadership roles at Xoft, TAE Life Sciences and other device companies. Rob holds a BS degree in Mechanical Engineering from UC Davis and an MBA with a strategic planning emphasis from UC Riverside.

“I’m absolutely thrilled to join G-Tech,” said Kirby. “I have known Steve for many years. I’ve been keeping a close eye on G-Tech’s progress from the days when the product was just an idea in Steve’s head, through these past several years of product development and clinical trials. It is truly remarkable how far such a small team has come in such a short amount of time. The chance to join the company at this pivotal time and play a role in commercializing this technology is a rare opportunity.”

G-Tech has developed a wireless wearable patch that measures GI motility of the stomach, small intestines and colon non-invasively over multiple days. Over 600 tests have been run under IRB approvals, resulting in 4 peer reviewed publications and numerous conference posters.

“Until now our team has focused on building the technology platform and confirming its clinical utility,” added Axelrod. “Rob’s hire is significant for us because it marks a turning point for G-Tech. We have succeeded in developing the GI motility tool that we set out to create. Now we can refocus our energy on building out the business so that our GI motility solution will positively impact patient’s lives and will potentially become a standard of care.”

The G-Tech patch system is not currently available for sale and does not have regulatory clearance or approval.

 

About G-Tech Medical

G-Tech Medical, Inc. is an early-stage medical device company dedicated to developing low-cost, non-invasive, diagnostic solutions for patients with chronic gastrointestinal disorders. G-Tech’s wearable patch-based “EKG for the Gut” will be used to diagnose underlying causes of GI disorders, allowing physicians to develop targeted therapies, thereby speeding relief to patients and significantly lowering the cost of health care. The company is headquartered at Fogarty Innovation, 2495 Hospital Drive, Suite 300, Mountain View, CA 94040. For further information, please visit www.GTechMedical.com or email info@gtechmedical.com.

 

#   #   #

 

Media Contact

Steve Axelrod

G-Tech Medical

650 269-1479

steve.axelrod@gtechmedical.com

G-Tech Medical Presents at the 2020 Digestive Disease Week

DDW 2020 logoG-Tech Medical will be in Chicago in May at the 2020 Digestive Disease Week with two posters in collaboration with researchers at Stanford University.

The first with findings from an ongoing longitudinal study of patients with Crohn’s disease demonstrates the uniqueness of each patient’s physiological gut print and its reproducibility as captured by G-Tech’s non-invasive patch system. The second abstract presents preliminary findings from a study measuring digestive vagal dysfunction in a patient population with gastroparesis.

G-Tech Medical’s Lindsay Axelrod Presents Her Abstract

Crohn's & Colitis Foundation logoG-Tech Medical’s Lindsay Axelrod presented her abstract with preliminary findings from an ongoing collaborative study with Stanford University supported by the Helmsley Charitable Trust. The study involves using non-invasive wireless electrode patches to read myoelectrical signals from the gut over 3 days in patients with Crohn’s disease. Forty patients presenting in flare, and 30 in remission will be tested at t=0,1,3 and 6 months.